• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

2024 R&D programmes in review: Sleeping sickness

Home > News

2024 R&D programmes in review: Sleeping sickness

Father with his son in rural setting
4 Mar 2025

DNDi and our partners are working to deliver breakthrough treatments and expedite access to eliminate sleeping sickness – for good. Our current goal is to finalize the development of acoziborole, an all-new, single-dose oral drug that can be given at the point of care, opening the possibility of simplified ‘test-and-treat’ approaches in primary healthcare settings. At the same time, we are continuing work to ensure broad access to fexinidazole for sleeping sickness caused by the parasites T.b. gambiense and T.b. rhodesiense, the more acute, less common form of the disease. 

Our progress in 2024 includes:

Icon of 5 people

Development

Acoziborole: The results of the safety study conducted with 1,208 non-parasitological-confirmed seropositive participants confirmed the favourable safety profile of acoziborole for the treatment of T.b.gambiense sleeping sickness. The recruitment of seropositive participants in StrogHAT – an intervention study to evaluate acoziborole’s safety, effectiveness, and feasibility – started in northern Equateur province in the Democratic Republic of the Congo. The recruitment of children with T.b.gambiense sleeping sickness aged between 1 and 14 years old also began in the second step of the ACOZI-KIDS study.

Acoziborole for children (ACOZI-KIDS): DNDi and partners successfully initiated step 2 of the study, which includes children weighing between 10 and 40 kilograms and aged between 1 and 14 years old. A total of 27 patients – 9 in step 1 and 18 in step 2 – were included in the trial as of December 2024. Targeted community awareness activities for implementation in early 2025 were designed to support study site recruitment to reach a global target inclusion of 35 participants.

Icon of hand holding a pill

Implementation

Fexinidazole for T.b. gambiense: DNDi facilitated data collection for the post-approval safety study in Guinea and the Democratic Republic of the Congo (DRC). The study was sponsored by Sanofi, implemented by the national sleeping sickness control programmes, and managed by WHO. National pharmacovigilance teams from the DRC, Central African Republic, Guinea, Angola, and South Sudan underwent a DNDi-supported three-day training at the Morocco pharmacovigilance centre to consolidate links between the teams and enable horizontal support by the DRC national pharmacovigilance centre. DNDi also supported a six-week distance training for eight participants from the five countries. Access activities related to fexinidazole for T.b. gambiense sleeping sickness were completed at the end of 2024.

A scientific article on the last clinical trial on fexinidazole for T.b. gambiense – notably including pregnant and breastfeeding women and a sub-group treated at home – will be published in The Lancet Global Health in April 2025.

Fexinidazole for T.b. rhodesiense: In June 2024, WHO updated its treatment guidelines to recommend fexinidazole as the first-line treatment for T.b. rhodesiense sleeping sickness. In the same month, the Democratic Republic of Congo registered fexinidazole for the treatment of T.b. rhodesiense sleeping sickness. Malawi granted approval for use of the drug at the end of 2024. Health professionals in other countries where T.b. rhodesiense is endemic are being trained on sleeping sickness diagnosis and the new treatment guidelines by WHO, DNDi, and national control programmes (SSNCP). It is expected that treatment with fexinidazole will expand commensurately in 2025. Pharmacovigilance activities for fexinidazole will be initiated by WHO, DNDi, and national control programmes in step with rollout of the new treatment. A scientific article from the study is expected to be published in The Lancet Global Health in April 2025.

Photo credit: Brent Stirton/Getty Images

Registration & access Clinical trials Sleeping sickness

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License